Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
Titel:
Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
Auteur:
Du Bois, A. Sehouli, J. Lund, B. Joly, F. Huober, J. Jensen, T.S. Levy, E. Heilmann, V. Boman, K. Hardy-Bessard, A.C. Burges, A. Mäenpää, J. Pujade-Lauraine, E. Pfisterer, J. Gropp, M. Staehle, A. Wimberger, P. Jackisch, C. Schmalfeldt, B. Belau, A. Loibl, S. Wollschlaeger, K. Canzler, U. Rochon, J.